Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents

Caroline Machado Kopruszinski, Jennifer Yanhua Xie, Nathan Mackenzie Eyde, Bethany Remeniuk, Sarah Walter, Jennifer Stratton, Marcelo Bigal, Juliana Geremias Chichorro, David William Dodick, Frank Porreca

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. Methods Rats were primed by a 7-day period of exposure to acute migraine therapies including sumatriptan and morphine. After an additional 14-day drug-free period, rats were exposed to putative migraine triggers including bright light stress (BLS) or nitric oxide (NO) donor in the presence or absence of TEV48125, a fully humanized CGRP antibody. Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured. Results BLS and NO donor challenge evoked delayed, long-lasting CA selectively in rats that were previously treated with sumatriptan or morphine. BLS produced a significant increase in CGRP in the plasma, but not CSF, in animals that were previously exposed to sumatriptan compared to saline controls. TEV48125 did not modify baseline tactile thresholds or produce behavioral side effects, but significantly inhibited both BLS- and NO donor-induced CA in animals that were previously primed with sumatriptan or morphine; an isotype control protein that does not bind CGRP had no effect. Interpretation These data suggest that acute migraine medications may promote MOH in susceptible individuals through CGRP-dependent mechanisms and that anti-CGRP antibodies may be a useful clinical strategy for the treatment of MOH.

Original languageEnglish (US)
Pages (from-to)560-570
Number of pages11
JournalCephalalgia
Volume37
Issue number6
DOIs
StatePublished - May 1 2017

Fingerprint

Secondary Headache Disorders
Nitric Oxide Donors
Calcitonin Gene-Related Peptide
Rodentia
Sumatriptan
Antibodies
Migraine Disorders
Hyperalgesia
Morphine
Light
Skin
Cerebrospinal Fluid
Touch
Outcome Assessment (Health Care)

Keywords

  • CGRP antibody
  • medication overuse headache
  • Migraine
  • rats
  • TEV48125

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Kopruszinski, C. M., Xie, J. Y., Eyde, N. M., Remeniuk, B., Walter, S., Stratton, J., ... Porreca, F. (2017). Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. Cephalalgia, 37(6), 560-570. https://doi.org/10.1177/0333102416650702

Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. / Kopruszinski, Caroline Machado; Xie, Jennifer Yanhua; Eyde, Nathan Mackenzie; Remeniuk, Bethany; Walter, Sarah; Stratton, Jennifer; Bigal, Marcelo; Chichorro, Juliana Geremias; Dodick, David William; Porreca, Frank.

In: Cephalalgia, Vol. 37, No. 6, 01.05.2017, p. 560-570.

Research output: Contribution to journalArticle

Kopruszinski, CM, Xie, JY, Eyde, NM, Remeniuk, B, Walter, S, Stratton, J, Bigal, M, Chichorro, JG, Dodick, DW & Porreca, F 2017, 'Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents', Cephalalgia, vol. 37, no. 6, pp. 560-570. https://doi.org/10.1177/0333102416650702
Kopruszinski, Caroline Machado ; Xie, Jennifer Yanhua ; Eyde, Nathan Mackenzie ; Remeniuk, Bethany ; Walter, Sarah ; Stratton, Jennifer ; Bigal, Marcelo ; Chichorro, Juliana Geremias ; Dodick, David William ; Porreca, Frank. / Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents. In: Cephalalgia. 2017 ; Vol. 37, No. 6. pp. 560-570.
@article{d5df5260e45a444da6a85559e4c6dfc7,
title = "Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents",
abstract = "Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. Methods Rats were primed by a 7-day period of exposure to acute migraine therapies including sumatriptan and morphine. After an additional 14-day drug-free period, rats were exposed to putative migraine triggers including bright light stress (BLS) or nitric oxide (NO) donor in the presence or absence of TEV48125, a fully humanized CGRP antibody. Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured. Results BLS and NO donor challenge evoked delayed, long-lasting CA selectively in rats that were previously treated with sumatriptan or morphine. BLS produced a significant increase in CGRP in the plasma, but not CSF, in animals that were previously exposed to sumatriptan compared to saline controls. TEV48125 did not modify baseline tactile thresholds or produce behavioral side effects, but significantly inhibited both BLS- and NO donor-induced CA in animals that were previously primed with sumatriptan or morphine; an isotype control protein that does not bind CGRP had no effect. Interpretation These data suggest that acute migraine medications may promote MOH in susceptible individuals through CGRP-dependent mechanisms and that anti-CGRP antibodies may be a useful clinical strategy for the treatment of MOH.",
keywords = "CGRP antibody, medication overuse headache, Migraine, rats, TEV48125",
author = "Kopruszinski, {Caroline Machado} and Xie, {Jennifer Yanhua} and Eyde, {Nathan Mackenzie} and Bethany Remeniuk and Sarah Walter and Jennifer Stratton and Marcelo Bigal and Chichorro, {Juliana Geremias} and Dodick, {David William} and Frank Porreca",
year = "2017",
month = "5",
day = "1",
doi = "10.1177/0333102416650702",
language = "English (US)",
volume = "37",
pages = "560--570",
journal = "Cephalalgia",
issn = "0333-1024",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Prevention of stress- or nitric oxide donor-induced medication overuse headache by a calcitonin gene-related peptide antibody in rodents

AU - Kopruszinski, Caroline Machado

AU - Xie, Jennifer Yanhua

AU - Eyde, Nathan Mackenzie

AU - Remeniuk, Bethany

AU - Walter, Sarah

AU - Stratton, Jennifer

AU - Bigal, Marcelo

AU - Chichorro, Juliana Geremias

AU - Dodick, David William

AU - Porreca, Frank

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. Methods Rats were primed by a 7-day period of exposure to acute migraine therapies including sumatriptan and morphine. After an additional 14-day drug-free period, rats were exposed to putative migraine triggers including bright light stress (BLS) or nitric oxide (NO) donor in the presence or absence of TEV48125, a fully humanized CGRP antibody. Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured. Results BLS and NO donor challenge evoked delayed, long-lasting CA selectively in rats that were previously treated with sumatriptan or morphine. BLS produced a significant increase in CGRP in the plasma, but not CSF, in animals that were previously exposed to sumatriptan compared to saline controls. TEV48125 did not modify baseline tactile thresholds or produce behavioral side effects, but significantly inhibited both BLS- and NO donor-induced CA in animals that were previously primed with sumatriptan or morphine; an isotype control protein that does not bind CGRP had no effect. Interpretation These data suggest that acute migraine medications may promote MOH in susceptible individuals through CGRP-dependent mechanisms and that anti-CGRP antibodies may be a useful clinical strategy for the treatment of MOH.

AB - Objective The objective of this study was the determination of the role of calcitonin gene-related peptide (CGRP) in the induction of medication overuse headache (MOH)-related migraine in an injury-free preclinical model. Methods Rats were primed by a 7-day period of exposure to acute migraine therapies including sumatriptan and morphine. After an additional 14-day drug-free period, rats were exposed to putative migraine triggers including bright light stress (BLS) or nitric oxide (NO) donor in the presence or absence of TEV48125, a fully humanized CGRP antibody. Cutaneous allodynia (CA) was used as an outcome measure and CGRP blood and cerebrospinal fluid (CSF) levels were measured. Results BLS and NO donor challenge evoked delayed, long-lasting CA selectively in rats that were previously treated with sumatriptan or morphine. BLS produced a significant increase in CGRP in the plasma, but not CSF, in animals that were previously exposed to sumatriptan compared to saline controls. TEV48125 did not modify baseline tactile thresholds or produce behavioral side effects, but significantly inhibited both BLS- and NO donor-induced CA in animals that were previously primed with sumatriptan or morphine; an isotype control protein that does not bind CGRP had no effect. Interpretation These data suggest that acute migraine medications may promote MOH in susceptible individuals through CGRP-dependent mechanisms and that anti-CGRP antibodies may be a useful clinical strategy for the treatment of MOH.

KW - CGRP antibody

KW - medication overuse headache

KW - Migraine

KW - rats

KW - TEV48125

UR - http://www.scopus.com/inward/record.url?scp=85019060938&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019060938&partnerID=8YFLogxK

U2 - 10.1177/0333102416650702

DO - 10.1177/0333102416650702

M3 - Article

C2 - 27206958

AN - SCOPUS:85019060938

VL - 37

SP - 560

EP - 570

JO - Cephalalgia

JF - Cephalalgia

SN - 0333-1024

IS - 6

ER -